S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Save $200 on MarketBeat All Access (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
Save $200 on MarketBeat All Access (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Save $200 on MarketBeat All Access (Ad)
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
North Korea notifies neighboring Japan it plans to launch satellite in coming days
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Save $200 on MarketBeat All Access (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
Save $200 on MarketBeat All Access (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Save $200 on MarketBeat All Access (Ad)
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
North Korea notifies neighboring Japan it plans to launch satellite in coming days
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Save $200 on MarketBeat All Access (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
Save $200 on MarketBeat All Access (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Save $200 on MarketBeat All Access (Ad)
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
North Korea notifies neighboring Japan it plans to launch satellite in coming days
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Save $200 on MarketBeat All Access (Ad)
10 Ways Entrepreneurs Can Navigate a Down Economy
PwC Australia sidelines 9 directors as leak of tax information investigated
Save $200 on MarketBeat All Access (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Drought-struck Barcelona quenches thirst with costly desalination
Save $200 on MarketBeat All Access (Ad)
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
North Korea notifies neighboring Japan it plans to launch satellite in coming days
NASDAQ:MYGN

Myriad Genetics (MYGN) Stock Forecast, Price & News

$22.29
+0.17 (+0.77%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$21.88
$22.76
50-Day Range
$17.56
$23.76
52-Week Range
$13.92
$28.18
Volume
396,500 shs
Average Volume
592,800 shs
Market Capitalization
$1.82 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.60

Myriad Genetics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
19.3% Upside
$26.60 Price Target
Short Interest
Bearish
4.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
0.61mentions of Myriad Genetics in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$151,047 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.63) to ($0.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

718th out of 1,010 stocks

Diagnostic Substances Industry

8th out of 16 stocks


MYGN stock logo

About Myriad Genetics (NASDAQ:MYGN) Stock

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Receive MYGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

MYGN Stock News Headlines

Exact Sciences Serves Investors Exactly What They Wished For (MYGN)
Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The
3 Free Stock Picks per Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Myriad Genetics (NASDAQ: MYGN)
3 Free Stock Picks per Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Positive Report for Myriad Genetics (MYGN) from Goldman Sachs
Where Myriad Genetics Stands With Analysts
Q1 2023 Myriad Genetics Inc Earnings Call
See More Headlines
Receive MYGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

MYGN Company Calendar

Last Earnings
5/03/2023
Today
5/29/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MYGN
CUSIP
62855J10
Employees
2,600
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$26.60
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+19.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-112,000,000.00
Pretax Margin
-24.01%

Debt

Sales & Book Value

Annual Sales
$678.40 million
Cash Flow
$0.19 per share
Book Value
$10.93 per share

Miscellaneous

Free Float
79,924,000
Market Cap
$1.82 billion
Optionable
Optionable
Beta
1.84

Social Links


Key Executives

  • Paul J. Diaz
    President, Chief Executive Officer & Director
  • Nicole LambertNicole Lambert
    Chief Operating Officer
  • R. Bryan Riggsbee
    Chief Financial Officer, Treasurer & Executive VP
  • Dale Muzzey
    Chief Scientific Officer
  • Kevin R. Haas
    Chief Technology Officer













MYGN Stock - Frequently Asked Questions

Should I buy or sell Myriad Genetics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MYGN shares.
View MYGN analyst ratings
or view top-rated stocks.

What is Myriad Genetics' stock price forecast for 2023?

4 brokerages have issued 12-month target prices for Myriad Genetics' shares. Their MYGN share price forecasts range from $24.00 to $32.00. On average, they predict the company's stock price to reach $26.60 in the next twelve months. This suggests a possible upside of 19.3% from the stock's current price.
View analysts price targets for MYGN
or view top-rated stocks among Wall Street analysts.

How have MYGN shares performed in 2023?

Myriad Genetics' stock was trading at $14.51 at the beginning of 2023. Since then, MYGN shares have increased by 53.6% and is now trading at $22.29.
View the best growth stocks for 2023 here
.

When is Myriad Genetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our MYGN earnings forecast
.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) posted its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02. The company had revenue of $181.20 million for the quarter, compared to analyst estimates of $171.56 million. Myriad Genetics had a negative trailing twelve-month return on equity of 7.42% and a negative net margin of 21.05%. The company's quarterly revenue was up 9.9% on a year-over-year basis. During the same period last year, the company posted ($0.14) earnings per share.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of -$0.36--$0.24 for the period, compared to the consensus EPS estimate of -$0.32. The company issued revenue guidance of $730.00 million-$750.00 million, compared to the consensus revenue estimate of $732.49 million.

What is Paul Diaz's approval rating as Myriad Genetics' CEO?

12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (17.32%), Wellington Management Group LLP (8.25%), State Street Corp (5.64%), Glenview Capital Management LLC (5.14%), Bank of America Corp DE (4.21%) and Dimensional Fund Advisors LP (3.34%). Insiders that own company stock include Alexander Ford, Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Jerry S Lanchbury, Nicole Lambert, Paul Parkinson, Richard Bryan Riggsbee and S Louise Phanstiel.
View institutional ownership trends
.

How do I buy shares of Myriad Genetics?

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $22.29.

How much money does Myriad Genetics make?

Myriad Genetics (NASDAQ:MYGN) has a market capitalization of $1.82 billion and generates $678.40 million in revenue each year. The company earns $-112,000,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis.

How many employees does Myriad Genetics have?

The company employs 2,600 workers across the globe.

Does Myriad Genetics have any subsidiaries?
The following companies are subsidiares of Myriad Genetics: Assurex Health Inc., Assurex Health Ltd, Counsyl, Crescendo Bioscience, Crescendo Bioscience LLC, Javelin Pharmaceuticals, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GK, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad Services GmbH, Myriad Women’s Health, Myriad Women’s Health Inc, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Rules-Based Medicine, and Sividon Diagnostics.
Read More
How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The official website for the company is www.myriad.com. The company can be reached via phone at (801) 584-3600, via email at sgleason@myriad.com, or via fax at 801-584-3640.

This page (NASDAQ:MYGN) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -